Clorox (CLX) Q3 2026 Earnings Call Transcript

Clorox said Q3 results were mixed and below expectations, with gross margin pressured by higher-than-expected supply chain costs and delayed cost savings tied to ERP stabilization. Full-year gross margin guidance was cut to down 250-300 bps, while Q4 faces a $20 million-$25 million oil-related headwind and about 130 bps of margin pressure. Offsetting that, GOJO adds about $200 million of Q4 revenue, but carries roughly 50 bps of year-one gross margin dilution and 150 bps of one-time Q4 acquisition costs.

Analysis

CLX is in a classic “foundation gets better before the P&L does” phase, but the market usually re-rates these setups only once the repair work starts showing up in scanner data and margin bridges. The key second-order issue is that ERP stabilization and cost inflation are colliding with a business that is already trying to re-engineer several franchises at once; that means management’s usual cost-offset playbook has less near-term elasticity than investors are used to underwrite. The result is a higher probability of multiple compression than earnings compression over the next 1-2 quarters, because the market will discount the risk that recovery keeps slipping one quarter at a time.

The biggest hidden winner is not necessarily GOJO itself, but the broader health-and-hygiene channel ecosystem: distributors, facilities, and private-label adjacent suppliers should see tighter shelf attention as Clorox reallocates management bandwidth and trade dollars toward higher-conviction brands. Conversely, category competitors in household, litter, and condiment-like food niches can exploit the window before CLX’s new price-pack architecture and RGM tests are fully proven. If oil stays elevated, the margin pressure is more dangerous than it looks because it hits both gross margin and advertising flexibility, forcing a harder choice between defending share and protecting EBITDA.

The contrarian piece: the selloff risk may be front-loaded, while the upside from execution normalization is more back-half weighted than consensus is likely modeling. If CLX gets even modest traction on on-shelf execution and the RGM tests show clear share lift, the stock can rebound quickly off a depressed base because the earnings revisions are already skewed lower. But absent evidence by the next 1-2 prints, this is a story where “good process” can coexist with bad stock performance.

Key Decisions for Investors

• Short CLX into the next 1-2 earnings windows if valuation still embeds a quick margin snapback; risk/reward favors the short until there is proof that shelf execution and RGM are translating into scan growth, not just TDP growth.
• For event-driven traders, buy CLX put spreads 1-2 quarters out to express downside on continued margin disappointment while capping premium risk; best setup is if crude stays firm and management is forced to revisit cost assumptions again.
• Pair trade: long GLAD / short CLX for a relative-value hedge against household staples margin pressure. GLAD has cleaner leverage to shelf execution and less operational noise, while CLX carries the burden of multi-quarter reset risk.
• If you want to own a defensive consumer staple, wait for CLX to show one clean quarter of both gross margin stabilization and velocity improvement before initiating; otherwise the stock remains a show-me story with weak near-term catalyst support.
• Monitor crude and freight as the first-order catalyst set: if oil rolls over meaningfully, cover tactical shorts in CLX quickly because the multiple could re-rate faster than the reported earnings improvement.